| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
| Targets |
As a chemical reagent, tetramethylammonium triacetoxyborohydride does not have a specific biological target. It is used in organic synthesis to prepare pharmaceutical intermediates and bioactive compounds. Its applications in drug discovery are indirect, as it facilitates the synthesis of complex molecules that may subsequently be evaluated for biological activity. The compound itself is not a pharmacologically active agent.
|
|---|---|
| ln Vitro |
Tetramethylammonium triacetoxyborohydride is a biochemical reagent that can be utilized in life science research as an organic compound or biological material.
Tetramethylammonium triacetoxyborohydride is a chemical reagent and does not possess intrinsic in vitro biological activity. Its value lies in its utility for synthesizing biologically active molecules, including pharmaceutical intermediates. It is used to reduce carbonyl compounds in the synthesis of complex organic molecules. The compound itself is not directly assayed for biological effects in cellular or biochemical systems. |
| ln Vivo |
This compound is not a pharmacologically active agent and does not have intrinsic in vivo activity. Its applications in vivo are limited to its use as a synthetic reagent for producing drug candidates that are subsequently evaluated in animal models. The compound is not administered to animals as a test compound.
|
| Enzyme Assay |
Cell-free enzyme/receptor binding assays are not applicable to tetramethylammonium triacetoxyborohydride as it is not a biologically active compound. It is a reducing agent used in organic synthesis. For compounds synthesized using this reagent, typical binding assays involve incubating the test compound with purified enzymes or receptors in buffered solutions, with binding affinity measured by SPR, ITC, or fluorescence-based methods.
|
| Cell Assay |
Cell-based assays are not directly performed on tetramethylammonium triacetoxyborohydride due to its lack of biological activity and potential cytotoxicity as a borohydride reagent. However, drug candidates synthesized using this reagent may be tested in cellular systems. Typical studies involve culturing cells in appropriate media, treating with the synthesized compound, and assessing various biological endpoints such as cell viability, proliferation, and signaling pathway activation.
|
| Animal Protocol |
In vivo animal studies are not conducted with tetramethylammonium triacetoxyborohydride itself, as it is a chemical reagent. Drug candidates synthesized from this intermediate may be evaluated in animal models for efficacy, pharmacokinetics, and toxicity. Typical studies involve oral or intravenous administration to rodents, with monitoring of plasma drug levels, tissue distribution, and disease-relevant endpoints. All studies follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Tetramethylammonium triacetoxyborohydride is a synthetic chemical reagent and is not subject to pharmacokinetic evaluation as a drug. Its physicochemical properties include a molecular weight of 263.10 g/mol. It appears as a white to off-white semi-solid to solid and should be stored at 2–8°C under inert atmosphere. The compound has high solubility in various organic solvents. It is moisture-sensitive and should be handled under anhydrous conditions.
|
| Toxicity/Toxicokinetics |
The toxicological profile of tetramethylammonium triacetoxyborohydride has not been extensively characterized. As a borohydride reagent, it may release toxic or flammable gases upon contact with water or acids. It may cause skin, eye, and respiratory tract irritation. Standard laboratory safety precautions should be observed, including the use of personal protective equipment (gloves, goggles, lab coat) and adequate ventilation. Ingestion and inhalation should be avoided. Appropriate first-aid measures should be in place.
|
| Additional Infomation |
Tetramethylammonium triacetoxyborohydride is not a drug but a valuable chemical reagent for organic synthesis. It is extensively used as a reducing agent for aldehydes and ketones. Its applications include the synthesis of Peloruside A and neurokinin substance P receptor antagonists. The compound's high solubility and selective reducing properties make it a useful tool in pharmaceutical research and development. It is not approved for clinical use.
|
| Molecular Formula |
C10H22BNO6
|
|---|---|
| Molecular Weight |
263.10
|
| Exact Mass |
263.154
|
| CAS # |
109704-53-2
|
| PubChem CID |
10858300
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
93-98ºC(lit.)
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
18
|
| Complexity |
206
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)O[BH-](OC(=O)C)OC(=O)C.C[N+](C)(C)C
|
| InChi Key |
ZWSJBUUORJFGHK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H9BO6.C4H12N/c1-4(8)11-7(12-5(2)9)13-6(3)10;1-5(2,3)4/h1-3H3;1-4H3/q-1;+1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (380.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8008 mL | 19.0042 mL | 38.0084 mL | |
| 5 mM | 0.7602 mL | 3.8008 mL | 7.6017 mL | |
| 10 mM | 0.3801 mL | 1.9004 mL | 3.8008 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
